Anterior Uveitis Global Market Report 2025

The anterior uveitis market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to the increasing prevalence of autoimmune disorders, greater awareness of eye health, improved access to healthcare, the growing use of corticosteroids and biologics, expanding research on immunological pathways, and a rising aging population.

The anterior uveitis market size is expected to see rapid growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing awareness of autoimmune diseases, the rising adoption of biologic therapies, a growing prevalence of inflammatory conditions, higher healthcare expenditure, and ongoing research into personalized medicine. Major trends include advancements in novel biologics, the adoption of corticosteroid delivery systems, innovations in advanced diagnostic imaging, personalized medicine approaches, targeted immunomodulators, the use of minimally invasive surgical techniques, and the development of digital health tools.

The increasing prevalence of autoimmune diseases is expected to drive growth in the anterior uveitis market. Autoimmune diseases occur when the immune system mistakenly attacks healthy cells and tissues, perceiving them as foreign threats. This abnormal response leads to inflammation and damage in various organs and systems. The rise in autoimmune diseases is attributed to genetic predisposition, environmental factors, lifestyle changes, and improved awareness leading to better diagnosis. Anterior uveitis is a common inflammatory eye condition associated with autoimmune diseases such as rheumatoid arthritis and ankylosing spondylitis. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. As a result, the growing incidence of autoimmune diseases is fueling the expansion of the anterior uveitis market.

Leading companies in the anterior uveitis market are advancing treatment approaches by developing innovative drug formulations such as eye drops to improve patient compliance, enhance drug delivery, and reduce inflammation with fewer side effects. Eye drops are widely used to manage anterior uveitis by controlling inflammation, alleviating pain, and preventing complications. For instance, in January 2024, Tarsier Pharma Ltd., an Israel-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the clinical trial protocol and statistical analysis plan of the Tarsier-04 Phase 3 trial. This trial aims to assess the effectiveness of TRS01 eye drops in treating non-infectious uveitis, including uveitic glaucoma. The Tarsier-04 trial is a multicenter, randomized, double-masked, active-controlled study enrolling up to 300 patients in the U.S., with the objective of demonstrating TRS01’s safety and efficacy, particularly in controlling inflammation without increasing the risk of glaucoma.

In January 2025, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, acquired Oxular Limited for an undisclosed amount. This acquisition enhances Regeneron's capabilities in ocular gene therapies by integrating an advanced delivery device, expediting the development of clinical treatments. By leveraging Oxular’s proprietary technologies, Regeneron aims to improve therapeutic precision and drive innovation in eye care. Oxular Limited is a UK-based biotech company specializing in drug and device treatments for retinal disorders, including anterior uveitis.

Major players in the anterior uveitis market are AbbVie Inc., Novartis AG, Amgen Inc., Aerie Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Bausch & Lomb Incorporated, Cipla Ltd., Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals Ltd., Santen Pharmaceutical Co. Ltd., HanAll Biopharma Co. Ltd., EyePoint Pharmaceuticals Inc., Kiora Pharmaceuticals Inc., Clearside Biomedical Inc., Oculis SA, Aldeyra Therapeutics Inc., Lux Biosciences Inc., Tarsier Pharma Ltd., Xoma Corporation.

North America was the largest region in the anterior uveitis market in 2024. The regions covered in anterior uveitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anterior uveitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anterior uveitis is an inflammatory condition affecting the eye's middle layer, including the iris and ciliary body. It can result from eye trauma, such as a direct injury or a foreign object, or be associated with systemic conditions such as rheumatoid arthritis, syphilis, tuberculosis, sarcoidosis, or viral infections (herpes simplex, herpes zoster, cytomegalovirus). In some cases, the cause remains idiopathic, with no identifiable underlying factor.

The primary treatment options for anterior uveitis include pharmacological therapies, surgical interventions, and biologic treatments. Pharmacological therapies involve medications to reduce inflammation and manage symptoms. Diagnosis is conducted through clinical evaluation, diagnostic imaging, and biomarker testing. The condition may have infectious or non-infectious origins and is managed in hospitals, clinics, and ambulatory surgical centers.

The anterior uveitis market research report is one of a series of new reports that provides anterior uveitis market statistics, including the anterior uveitis industry's global market size, regional shares, competitors with a anterior uveitis market share, detailed anterior uveitis market segments, market trends and opportunities, and any further data you may need to thrive in the anterior uveitis industry. This anterior uveitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anterior uveitis market consists of revenues earned by entities by provide services such as slit-lamp examinations, optical coherence tomography (OCT), ultrasound biomicroscopy, corticosteroid administration, and glaucoma management. The market value includes the value of related goods sold by the service provider or included within the service offering. The anterior uveitis market also includes sales of corticosteroids (topical and systemic), non-steroidal anti-inflammatory drugs (NSAIDS), and immunosuppressive drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.